Menu

Topics

Connect

Comments

Want to discuss? Please read our Commenting Policy first.

Guelph-based Linamar to start making medical equipment

A Linamar facility in Guelph, Ont., May 8, 2014. THE CANADIAN PRESS / Stephen C. Host

Guelph-based auto parts manufacturer Linamar Corporation is getting into the medical market.

Story continues below advertisement

It announced an agreement with Synaptive Medical Inc. on Tuesday and will be investing $5 million into the Toronto-based company.

The deal will also see Linamar manufacture two of Synaptive’s products: a robotically controlled digital microscope and a head-only MRI system.

Both products will be made at Linamar’s new innovation hub on Woodlawn Road in Guelph.

“This strategic partnership is a great first step for us into the opportunistic medical and biotech market, given the growing and ageing population and the ongoing demand for new, innovative and cost-effective solutions to our growing medical needs,” Linamar CEO Linda Hasenfratz said in a statement.

“Synaptive is truly a global innovation leader in the medical marketplace and we are excited to embark on this partnership with them.”

Story continues below advertisement

Linamar said the hands-free Modus V microscope supports a wide range of surgical approaches and offers a larger field of view, a higher depth of field and more natural colour reproduction. It also allows for much shorter surgery times.

The Evry MRI system has yet to receive regulatory clearance but is designed to reduce installation and operational costs, and can be used in critical and acute situations, according to Linamar.

“We recognize the importance of scaling manufacturing processes in surgical planning and navigation,” said Synaptive’s president Cameron Pirron.

“We are extremely excited about this agreement with Linamar Corporation, a demonstrated leader in device technology manufacturing, marking the advancement of Synaptive’s manufacturing efforts as we work to develop innovative technologies for surgeons worldwide.”

Advertisement

You are viewing an Accelerated Mobile Webpage.

View Original Article